Full metadata record

DC FieldValueLanguage
dc.contributor.author김인산-
dc.contributor.authorSeung-Yoon Park-
dc.date.accessioned2021-06-09T04:22:08Z-
dc.date.available2021-06-09T04:22:08Z-
dc.date.issued2019-06-
dc.identifier.citationVOL 452-58-
dc.identifier.issn0304-3835-
dc.identifier.other52703-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/69359-
dc.description.abstractMyeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.-
dc.publisherCancer letters-
dc.titleHarnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.-
dc.typeOther-
dc.relation.page5158-
Appears in Collections:
KIST Publication > ETC
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE